Meghan Thomas

Head of Clinical Development at Argenica Therapeutics - Perth, Western Australia, Australia

Meghan Thomas's Colleagues at Argenica Therapeutics
Emma Waldon

CFO & Company Secretary

Contact Emma Waldon

Liddy McCall

Non Executive Director

Contact Liddy McCall

Liz Dallimore

CEO & Managing Director

Contact Liz Dallimore

Meghan Thomas's Contact Details
HQ
Location
Perth,Western Australia,6000,Australia
Company
Argenica Therapeutics
Meghan Thomas's Company Details
Argenica Therapeutics logo, Argenica Therapeutics contact details

Argenica Therapeutics

Perth, Western Australia, Australia • 7 Employees
Pharmaceuticals

Argenica is developing and seeking to commercialise a "best in class" neuroprotective cationic arginine- rich peptide therapy to improve outcomes in stroke patients.Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity.Current treatment options remain limited to restoring blood flow through clot removal by tPA (alteplase) thrombolysis and mechanical thrombectomy. Despite considerable research, there are no marketed drugs capable of protecting the brain from damage following stroke. Therefore, the search for widely applicable and effective neuroprotective drugs for stroke patients remains an urgent unmet need and priority.Argenica has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy. Specifically, Argenica has developed a neuroprotective therapeutic, ARG-007, that • Slows brain tissue death due to inadequate blood supply• Preserves brain cells and axons• Extends the treatment time window for stroke patients • Is not toxic• Can be delivered in the field by first responders The Company also intends to explore the development and commercialisation of cationic arginine-rich peptides in other neural injury conditions such as perinatal hypoxia, traumatic brain injury, spinal cord injury, and in patients undergoing endovascular procedures that carry a risk of dislodging material from a diseased artery or triggering an embolus to lodge in a brain artery and thereby causing a stroke.

Details about Argenica Therapeutics
Frequently Asked Questions about Meghan Thomas
Meghan Thomas currently works for Argenica Therapeutics.
Meghan Thomas's role at Argenica Therapeutics is Head of Clinical Development.
Meghan Thomas's email address is ***@argenica.com.au. To view Meghan Thomas's full email address, please signup to ConnectPlex.
Meghan Thomas works in the Pharmaceuticals industry.
Meghan Thomas's colleagues at Argenica Therapeutics are Samantha South, Emma Waldon, Liddy McCall, Liz Dallimore and others.
Meghan Thomas's phone number is
See more information about Meghan Thomas